Chemoradiotherapy and Increased Prescription Dose in Esophageal Squamous Cell Cancer: A Retrospective Study

Table 5

Subgroup analysis for the survival of the patients.

Characteristics		(%)	3 y LRFFS		3 y PFS		3 y OS
			%		%		%
Sex	Male	21 (80.8)	63.6	0.051	57.9	0.034	68.4	0.530
	Female	5 (19.2)	100		100		80
Age (years)	≥75	3 (11.5)	66.7	0.771	67.1	0.862	76.5	0.069
	<75	23 (88.5)	50.0		50.0		33.3
Tumor localization	Cervical	4 (15.4)	66.7	0.059	66.7	0.064	100	<0.001
	Upper thoracic	8 (30.8)	85.7		85.7		100
	Middle thoracic	11 (42.3)	46.8		46.8		36.4
	Lower thoracic	3 (11.5)	66.7		66.7		100
T stage	3	8 (38.1.)	85.7	0.202	68.6	0.895	72.9	0.927
	4	13 (61.9)	73.8		73.8		75.5
Clinical stage	III	15 (65.2)	60.3	0.067	60.3	0.067	63.8	0.010
	IV	8 (34.8)	83.3		85.7		100
Combined with Endostar	Yes	14 (53.8)	71.4	0.849	64.3	0.400	78.6	0.201
	No	12 (46.2)	68.8		53.5		61.1

LRFFS: locoregional failure-free survival; PFS: progression-free survival; OS: overall survival.